Topic • 4 articles

Pharma & FDA

Drug approvals, recalls, regulation, biotech pipelines, and the commercial side of medicine.

Why this topic matters right now

This topic is gaining attention due to recent developments, public interest, and its broader impact across related areas. Stay informed with our comprehensive coverage and analysis of the latest trends and implications.

Latest coverage

How Firm Is the iPLEDGE REMS? Assessing the Near-Term Outlook

Apr 6, 2026 Jacob Ellis

The FDA’s iPLEDGE REMS is designed to curb embryo‑fetal risk. What is actually known about its status—and how likely is formal confirmation in the coming week?

Torrent Pharmaceuticals Cited by FDA for Adulterated Finished Drugs

Apr 6, 2026 Lucas Morris

U.S. regulators have flagged Torrent Pharmaceuticals Limited for CGMP violations tied to adulterated finished medicines, raising quality and oversight questions.

How Every Cure’s Drug Search Aims to Rewrite Rare Disease Treatment

Mar 29, 2026 Grace Holloway

A small nonprofit is trying to match existing drugs to overlooked rare diseases, challenging how new treatments are usually found and funded.

FDA clears rare disease drug as Washington scrutiny on patents intensifies

Mar 27, 2026 Lucas Morris

A new FDA approval for a rare genetic disorder lands as senators press patent officials and lawmakers push to cap insulin costs.